Ting Cheng: Why Gene Therapy Needs Reinvention Before It Can Reach Millions
Ting Cheng, Principal Scientist at Johnson & Johnson, AI/Tech and Pharma/Healthcare Investor, shared on LinkedIn:
”Pfizer approved a hemophilia gene therapy in 2025.
Then pulled it — because not a single patient ever received it after approval.
In that same seven-month window, five major pharma companies spent over $10 billion acquiring pre-commercial cell therapy companies, before any of them had treated a paying patient.
Both things are true at once, and the article breaks down what that actually means: the current generation’s manufacturing and pricing model is broken, not the underlying biology — which already has 34,000 treated patients and 14 billion USD in 2024 revenue behind five approved drugs.
The next wave is targeting something structurally different — a $150 billion market the current approach was never built to reach.
Read the full breakdown here.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?